State-of-the-art nuclear medicine and pipeline industry developments

22nd January 2021 01:00 PM - 04:00 PM (GMT+01:00) Europe/London

We are going virtual!

This one-day virtual event will provide a platform for industry to demonstrate their current products and discuss their pipeline products that will soon be available. This will allow participants to become aware of what the state-of-the-art products in nuclear medicine are and help them decide what may best suit their needs to improve services.

View event programme

Educational aims:

To become aware of state-of-the-art nuclear medicine radiopharmaceuticals and the appropriate indications for use of these products
To become aware of state-of-the- art imaging cameras to evaluate the advantages and limitations of products
To learn about current software packages and what functions these can provide

This event is FREE to attend for all BIR members and non-members

If you are having issues registering for the event please create or login to your MyBIR account via this link and then register for the event after you have logged in. If you are still experiencing any issues please email conference@bir.org.uk

Venue

Speakers

Advanced Accelerator Applications

Advanced Accelerator Applications, S.A. (AAA), a Novartis company, is an innovative medicines company developing targeted radioligand therapies and precision imaging radioligands for oncology. We are committed to transforming patients’ lives by leading innovation in nuclear medicine. AAA currently has over 1,000 employees working across 31 sites in 12 countries (Canada, France, Germany, Israel, Italy, the Netherlands, Poland, Portugal, Spain, Switzerland, the UK and the US). The company also has global manufacturing capabilities with 19 facilities in eight countries, and six research & development sites. For more information, please visit: https://www.adacap.com/.

Bayer

Bayer’s Radiology business is well placed to be the partner of choice in helping NHS trusts to address the many challenges faced today including the increasing need for governance to demonstrate best practice and improving patient care within increasing financial constraints. With market-leading contrast media and power injector systems, Bayer is able to offer innovative patient care and with the addition of its informatics platform, it can support radiology departments in driving protocol standardisation and easily accessible audit data that enable departments to meet further challenges faced around contrast and radiation dose management. 0118 2063999 www.radiology.bayer.co.uk

Blue Earth Diagnostics

Blue Earth Diagnostics is a leading molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. The company’s first approved and commercially available product is Axumin® (fluciclovine F 18). Blue Earth Diagnostics is a subsidiary of Bracco Imaging S.p.A..

GE Healthcare

GE Healthcare is a leading provider of medical imaging, monitoring, and life science technologies. GE Healthcare enables precision health in diagnostics, therapeutics and monitoring through intelligent devices, data analytics, applications and services to help providers, researchers and life sciences companies in their mission to improve outcomes for patients around the world.

MIM Software Inc.

MIM Software provides solutions in Radiology, Nuclear Medicine, and Radiation Oncology. MIM’s products emphasize the importance of quantitation, collaboration, and data management to provide physicians with the necessary information needed to generate confident clinical guidance and to inform effective treatments. MIM SurePlan™ products provide timesaving tools for organ and tumor segmentation, deformable registration, and voxel-based dosimetry. SurePlan offers reporting solutions that provide more information about the treatment course. https://go.mimsoftware.com/eu/personalized-dosimetry

OncoBeta

OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device and radiochemical company specialized in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® GmbH has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards. Since 2019 OncoBeta® GmbH produces tungsten (wolfram)-188/rhenium-188 (188W/188Re) Generators for commercial use. Find out more about the Rhenium-SCT® at www.oncobeta.com Follow us on social media: LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/ Facebook: https://www.facebook.com/OncoBeta/

Philips Healthcare

Enabling better health and better care at lower cost Philips is a leading health technology company focused on improving people`s lives across the health continuum - from healthy living and prevention, to diagnosis, treatment and home care. Applying advanced technologies and deep clinical and consumer insights, Philips delivers integrated solutions that improve people`s health and enable better outcomes. Partnering with its customers, Philips seeks to transform how healthcare is delivered and experienced. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. www.philips.co.uk/healthcare

Siemens Healthineers

At Siemens Healthineers, our purpose is to enable healthcare providers to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, and improving patient experience, all enabled by digitalising healthcare. An estimated 5 million patients globally everyday benefit from our innovative technologies and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics and molecular medicine, as well as digital health and enterprise services. We are a leading medical technology company with over 170 years of experience and 18,000 patents globally. With more than 48,000 dedicated colleagues in 75 countries, we will continue to innovate and shape the future of healthcare. For more information and latest product line, please visit https://www.siemens-healthineers.com/en-uk/